CIBA LAUNCHING FASTER ACTING DICLOFENAC-BASED PRESCRIPTION NSAID
This article was originally published in The Tan Sheet
CIBA LAUNCHING FASTER ACTING DICLOFENAC-BASED PRESCRIPTION NSAID under the brandname Cataflam. Approved by FDA on Nov. 2,4, 1993, Cataflam (diclofenac potassium) is a slightly altered version of Ciba's Voltaren (diclofenac sodium), which has been marketed in the U.S. as a nonsteroidal anti-inflammatory agent since 1988. Cataflam was introduced to the trade in early February.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC